1. Home
  2. PSFE vs AKBA Comparison

PSFE vs AKBA Comparison

Compare PSFE & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Paysafe Limited

PSFE

Paysafe Limited

HOLD

Current Price

$6.41

Market Cap

347.5M

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$0.93

Market Cap

343.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PSFE
AKBA
Founded
1996
2007
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
347.5M
343.4M
IPO Year
2020
2014

Fundamental Metrics

Financial Performance
Metric
PSFE
AKBA
Price
$6.41
$0.93
Analyst Decision
Hold
Strong Buy
Analyst Count
4
3
Target Price
$8.69
$4.67
AVG Volume (30 Days)
292.3K
8.6M
Earning Date
05-13-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
93.94
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$8.15
N/A
Revenue Next Year
$6.25
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.95
$0.81
52 Week High
$13.56
$3.19

Technical Indicators

Market Signals
Indicator
PSFE
AKBA
Relative Strength Index (RSI) 49.68 N/A
Support Level $6.56 N/A
Resistance Level $6.94 N/A
Average True Range (ATR) 0.23 0.00
MACD 0.07 0.00
Stochastic Oscillator 67.53 0.00

Price Performance

Historical Comparison
PSFE
AKBA

About PSFE Paysafe Limited

Paysafe Ltd is an integrated payments platform. Its core purpose is to enable businesses and consumers to connect and transact seamlessly through capabilities in payment processing, digital wallet, and online cash solutions. The company's reportable segments are Merchant Solutions and Digital Wallets. The Merchant Solutions segment, which derives maximum revenue, services markets in North America, Canada and Europe. The Digital Wallets segment services markets in Europe, UK, North America and Latin America. It derives a majority of revenue from the USA followed by Germany, the UK, and all other countries.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Share on Social Networks: